VITROLIFE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 184.7 SEK | +5.54% |
|
-1.49% | -5.14% |
| May. 22 | Sweden's Vitrolife Wraps Up Purchase of Software Group eFertility | MT |
| May. 22 | Vitrolife AB (OM:VITR) acquired Stb Zorg B.V. | CI |
| Sales 2024 * | 3.6B 342M | Sales 2025 * | 3.98B 378M | Capitalization | 25.01B 2.38B |
|---|---|---|---|---|---|
| Net income 2024 * | 530M 50.36M | Net income 2025 * | 677M 64.33M | EV / Sales 2024 * | 7.11 x |
| Net Debt 2024 * | 600M 57.02M | Net cash position 2025 * | 103M 9.82M | EV / Sales 2025 * | 6.26 x |
| P/E ratio 2024 * |
47.2
x | P/E ratio 2025 * |
37
x | Employees | 1,132 |
| Yield 2024 * |
0.73% | Yield 2025 * |
0.75% | Free-Float | 55.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vitrolife AB
More news
| 1 day | +5.54% | ||
| 1 week | -1.49% | ||
| 1 month | +11.06% | ||
| 3 months | +2.27% | ||
| 6 months | +1.32% | ||
| Current year | -5.14% |
1 week
171.20
189.40
1 month
164.40194.30
Current year
156.00205.40
1 year
123.90244.20
3 years
123.90585.00
5 years
112.30585.00
10 years
20.75585.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bronwyn Brophy
CEO | Chief Executive Officer | - | 23-07-31 |
Patrik Tolf
DFI | Director of Finance/CFO | 54 | 21-12-31 |
| Chairman | 68 | 15-05-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 19-05-01 | |
| Chairman | 68 | 15-05-06 | |
| Director/Board Member | 64 | 18-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 232 M€ | +12.88% | ||
| 0.02% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 184.7 | +5.54% | 458,370 |
| 24-05-30 | 175 | -0.17% | 200,707 |
| 24-05-29 | 175.3 | -3.73% | 170,548 |
| 24-05-28 | 182.1 | -2.31% | 58,450 |
| 24-05-27 | 186.4 | -0.59% | 25,969 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT
More quotes
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
2024-07-12
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
184.7
SEK
Average target price
231.7
SEK
Spread / Average Target
+25.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.14% | 2.37B | |
| -3.43% | 12.45B | |
| -3.17% | 8.22B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| -59.94% | 2.68B | |
| +11.23% | 2.68B | |
| +18.91% | 2.06B | |
| -7.56% | 1.8B | |
| +3.07% | 1.6B |
- Stock Market
- Equities
- VITR Stock
